Glembatumumab Vedotin (CDX-011, CR011-vcMMAE): On The Brink Of Targeted Therapy For Triple-Negative Breast Cancer?
11:47 Share

A phase I/II study of the antibody-drug conjugate glembatumumab vedotin (CDX-011 or CR011-vcMMAE) in patients with locally advanced or metastatic breast cancer, reveals an acceptable safety profile and promising clinical activity in GPNMB expressing breast cancer.